EGFR and head and neck cancer: Currently, there are two FDA approved anti-EGFR mAbs for cancer therapies in the USA, Cetuximab and Panitumumab for metastatic colorectal cancer (9, 106, 107), and Cetuximab for locoregional head and neck cancer (92).